Mayer Brown represented the London-based GW Pharmaceuticals plc, a biopharmaceutical company, in a $101.1 million US public offering and listing of American Depositary Shares on the Nasdaq Global Market in an offering led by Morgan Stanley & Co. LLC and Cowen and Company, LLC. The transaction follows GW Pharmaceuticals’ US initial public offering in May 2013, on which Mayer Brown also represented the company.

The Mayer Brown team was led by Corporate & Securities partner David Bakst (New York) and included: Corporate & Securities – partner Richard Smith (London) and associate George Rudy (New York); Tax Transactions & Consulting – partners Jason Bazar (New York) and Sandy Bhogal (London) and associates Jared Goldberger (New York) and Benjamin Fryer (London); and Intellectual Property – partner Richard Assmus and associate Jonathan Kim (both Chicago).

http://www.mayerbrown.com/GW-Pharmaceuticals-Nasdaq-offering/